Q-omics provides the consensus-scored ANKRD33B profile across patient tissues and cancer cell-line models. ANKRD33B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD33B is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ANKRD33B RNA expression shows 19,329 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where ANKRD33B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD33B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD33B survival associations across molecular data types. ANKRD33B RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD33B RNA expression–survival associations across cancer types. High ANKRD33B expression shows unfavorable associations in UVM, UCEC, THCA and OV, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD33B RNA expression.
This table summarizes ANKRD33B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD33B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD33B shows lower tumor expression in COAD, LUAD, UCEC, BRCA and BLCA and higher tumor expression in KIRC. The KIRC box plot shows higher ANKRD33B RNA expression in tumor versus normal tissue (log2 FC = +1.225, t-test p < 0.001).
This table shows molecular features associated with ANKRD33B in patient tissues and cancer cell lines. In patient samples, ANKRD33B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD33B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
